US Drug Recall Register
Class II · Moderate risk Terminated Initiated Feb 7, 2022 (5 years ago)

Erythromycin Topical Gel USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: Lot not meeting specification for Unknown Max Related Compounds.

What was recalled

Erythromycin Topical Gel USP, 2%, Net Wt 30 g tube, Rx only, Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310, Distributed by: McKesson Corporation, dba Sky Packaging, 4971 Southridge Blvd., Suite 101, Memphis, TN 38141, NDC 63739-053-66.

Recalling firm
Teligent Pharma, Inc.
NDC code
63739-053-66
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0716-2022

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Erythromycin recalls

See all
Class II · Moderate risk Ongoing

Erythromycin Tablets

Reason CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc NDC 70710-1048-3 D-0545-2026
Class II · Moderate risk Ongoing

Erythromycin Tablets

Reason CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc NDC 70710-1047-3 D-0544-2026
Class II · Moderate risk Ongoing

Erythromycin Topical Gel USP

Reason CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

McKesson Corporation dba McKesson Drug Company NDC 63739-053-68 D-0851-2022